A fish in troubled waters: FDA weighs cancer risk of calcitonin salmon meds
This article was originally published in Scrip
While Novartis and Unigene Laboratories, along with its US distribution partner Upsher Smith, would be wounded if the FDA decides to limit the use of calcitonin salmon medicines used to treat postmenopausal osteoporosis – or even force the drugs from the US market – companies in the midst of developing those products, like Tarsa Therapeutics, may ultimately suffer the greatest consequences.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.